Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose

Community Genetics

Volumn 10, Issue 1, 2006, Pages 32-37

  Tanira, Musbah O ^a   Al Mukhaini, Mohammed K ^b   Al Hinai, Ali T ^a   Al Balushi, Khalid A ^a   Ahmed, Ikhlas S ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b ROYAL HOSPITAL   (Oman)

Author keywords

CYP2C9 genotype; Warfarin treatment

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; WARFARIN;

EID: 33845765706     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096279     Document Type: Article

References (35)

1. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
2. Van der Meer F, Rosendaal F, Vandenbroucke J, Briet E: Bleeding complications in oral anticoagulation therapy. Arch Intern Med 1993;153:1557-1562.
3. British Committee for Standards in Hematology: Guidelines on oral anticoagulation. Br J Haematol 1998;101:374.
4. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.
5. Budavari S (ed): The Merck Index, ed 11. Rahway, Merck, 1989.
6. Schroedter IC, Williams G: Frequency of cytochrome P450 CYP2C9 alleles in patients undergoing routine coagulation screening in a large tertiary care facility. J Mol Diagn 1999;1:41.
7. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
8. Takahashi H, Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
9. Hirsch J, Dalen DE, Anderson D, et al: Oral anticoagulants. Chest 2001;119(suppl 1):8-21.
10. James AH, Britt RP, Raskino CL, Thompson SG: Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704-706.
11. Steward DJ, Haining RJ, Hanne KR: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367.
12. Retti AE, Korzekwa KR, Kunze KH, Lawrence RF, Eddy AC, et al: Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-59.
13. Haining R, Hunter A, Veronese M, Targer W, Rettie A: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression purification, structural characterization, substrate sterioselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447.
14. Crespi Cl, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH. Pharmacogenetics 1997;7:203-210.
15. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants. Pharmacogenetics 2000;10:95-104.
16. Imai J, Jeiri I, Mamiya K, Miyahara S, Furuumi H, Naba E, et al: Polymorphism of cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CY2C9 locus. Pharmacogenetics 2000;10:85-89.
17. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54:1257-1270.
18. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382-387.
19. Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003;33(suppl 2):23-30.
20. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.
21. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the Cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-439.
22. Wang SL, Huang J, Lai MD, Tsai JJ: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-42.
23. Goldstein JA: CYP2C9 polymorphisms and CYP2C9*2 genotyping primers. Br J Clin Pharmacol 2002;53:409-410.
24. Simsek M, Tanira MO, Al-Baloushi KA, Al-Barwani HS, Lawatia KM, Bayoumi RA: A precaution in the detection of heterozygotes by sequencing: comparison of automated DNA sequencing and PCR-restriction fragment length polymorphism methods. Clin Chem 2001;47:134-137.
25. Taube J, Halsall D, Baglin T: Influence of cytochrome CYP2C9 polymorphisms on warfarin sensitivity and risk of overcoagulation in patients with long term treatment. Blood 2000;96:1816-1819.
26. Ferrari P: Pharmacogenomics: a new approach to individual therapy of hypertension. Curr Opin Nephrol Hypertens 1998;7:217-222.
27. Roden DM, George AL: The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002;1:37-44.
28. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG: Frequency of cytochrome P450 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-280.
29. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.
30. Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, Yip AS, Liang R: Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98:2584-2587.
31. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349.
32. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G: Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000;84:775-778.
33. Takahashi H, Echizen H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3:202-214.
34. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001;52:447-450.
35. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-631.